These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30127467)

  • 21. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
    Picardi A; Fabritiis Pd Pd; Cudillo L; Dentamaro T; Cupelli L; Ballatore G; Venditti A; Caravita T; Cristina Cox M; Catalano G; Amadori S
    Hematol J; 2004; 5(1):24-31. PubMed ID: 14745426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Al Malki MM; Nathwani N; Yang D; Armenian S; Dadwal S; Salman J; Mokhtari S; Cao T; Sandhu K; Rouse M; Mei M; Ali H; Parker P; Alvarnas J; Smith E; Donnell MO; Marcucci G; Snyder D; Nademanee A; Forman SJ; Stein A; Nakamura R
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1828-1835. PubMed ID: 29753158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
    Shimoni A; Nagler A
    Leuk Lymphoma; 2009 Sep; 50(9):1395-6. PubMed ID: 19672777
    [No Abstract]   [Full Text] [Related]  

  • 25. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
    Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
    Rabian F; Porcher R; Sicre de Fontbrune F; Lioure B; Laplace A; Nguyen S; Tabrizi R; Vigouroux S; Tomowiak C; Maillard N; Suarez F; Delage J; Peffault de Latour R; Socié G;
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1721-1724. PubMed ID: 27246370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin).
    Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y
    Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.
    Junghanss C; Marr KA; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Storb R
    Biol Blood Marrow Transplant; 2002; 8(9):512-20. PubMed ID: 12374456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
    Olsson RF; Logan BR; Chaudhury S; Zhu X; Akpek G; Bolwell BJ; Bredeson CN; Dvorak CC; Gupta V; Ho VT; Lazarus HM; Marks DI; Ringdén OT; Pasquini MC; Schriber JR; Cooke KR
    Leukemia; 2015 Aug; 29(8):1754-62. PubMed ID: 25772027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second allogeneic stem cell transplantation in hematologic malignancies: a single-center experience.
    Chueh HW; Lee SH; Sung KW; Yoo KH; Koo HH
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):424-9. PubMed ID: 23887021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
    Kobbe G; Schneider P; Aivado M; Zohren F; Schubert D; Fenk R; Neumann F; Kronenwett R; Pape H; Rong A; Royer-Pokora B; Hildebrandt B; Germing U; Gattermann N; Heyll A; Haas R
    Exp Hematol; 2002 Nov; 30(11):1346-53. PubMed ID: 12423689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
    Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J
    Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!
    Kindwall-Keller TL; Ballen KK
    Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut decontamination during allogeneic hematopoietic stem cell transplantation and the risk of acute graft-versus-host disease.
    Gjærde LK; Schmidt M; Sengeløv H
    Bone Marrow Transplant; 2018 Aug; 53(8):1061-1064. PubMed ID: 29491465
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.